Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo

(European Society for Medical Oncology) A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.